Trial Profile
On target management for secondary hyperparathyroidism by two calcimimetics (HP2C study)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2017
Price :
$35
*
At a glance
- Drugs Cinacalcet (Primary) ; Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Acronyms HP2C study
- 04 Oct 2017 New trial record